These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 25589345

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A potential target for liver cancer management, lysophosphatidic acid receptor 6 (LPAR6), is transcriptionally up-regulated by the NCOA3 coactivator.
    Zheng X, Jia Y, Qiu L, Zeng X, Xu L, Wei M, Huang C, Liu C, Chen L, Han J.
    J Biol Chem; 2020 Feb 07; 295(6):1474-1488. PubMed ID: 31914406
    [Abstract] [Full Text] [Related]

  • 4. Lysophosphatidic acid receptor expression and function in human hepatocellular carcinoma.
    Sokolov E, Eheim AL, Ahrens WA, Walling TL, Swet JH, McMillan MT, Simo KA, Thompson KJ, Sindram D, McKillop IH.
    J Surg Res; 2013 Mar 07; 180(1):104-13. PubMed ID: 23182454
    [Abstract] [Full Text] [Related]

  • 5. Novel lysophosphatidic acid receptor 6 antagonists inhibit hepatocellular carcinoma growth through affecting mitochondrial function.
    Gnocchi D, Kapoor S, Nitti P, Cavalluzzi MM, Lentini G, Denora N, Sabbà C, Mazzocca A.
    J Mol Med (Berl); 2020 Feb 07; 98(2):179-191. PubMed ID: 31863151
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of lysophosphatidic acid receptor 6 upregulated by the choline-deficient l-amino acid-defined diet prevents hepatocarcinogenesis in mice.
    Gnocchi D, Afonso MB, Cavalluzzi MM, Lentini G, Ingravallo G, Sabbà C, Rodrigues CMP, Mazzocca A.
    Mol Carcinog; 2023 May 07; 62(5):577-582. PubMed ID: 36752344
    [Abstract] [Full Text] [Related]

  • 7. HBx-mediated miR-21 upregulation represses tumor-suppressor function of PDCD4 in hepatocellular carcinoma.
    Qiu X, Dong S, Qiao F, Lu S, Song Y, Lao Y, Li Y, Zeng T, Hu J, Zhang L, Zhang L, Fan H.
    Oncogene; 2013 Jul 04; 32(27):3296-305. PubMed ID: 23604124
    [Abstract] [Full Text] [Related]

  • 8. Combined functional genome survey of therapeutic targets for hepatocellular carcinoma.
    Satow R, Shitashige M, Kanai Y, Takeshita F, Ojima H, Jigami T, Honda K, Kosuge T, Ochiya T, Hirohashi S, Yamada T.
    Clin Cancer Res; 2010 May 01; 16(9):2518-28. PubMed ID: 20388846
    [Abstract] [Full Text] [Related]

  • 9. Homeobox B9 is overexpressed in hepatocellular carcinomas and promotes tumor cell proliferation both in vitro and in vivo.
    Li F, Dong L, Xing R, Wang L, Luan F, Yao C, Ji X, Bai L.
    Biochem Biophys Res Commun; 2014 Feb 07; 444(2):241-7. PubMed ID: 24462859
    [Abstract] [Full Text] [Related]

  • 10. RNA interference against cancer/testis genes identifies dual specificity phosphatase 21 as a potential therapeutic target in human hepatocellular carcinoma.
    Deng Q, Li KY, Chen H, Dai JH, Zhai YY, Wang Q, Li N, Wang YP, Han ZG.
    Hepatology; 2014 Feb 07; 59(2):518-30. PubMed ID: 23929653
    [Abstract] [Full Text] [Related]

  • 11. RASSF1A expression inhibits the growth of hepatocellular carcinoma from Qidong County.
    Xue WJ, Li C, Zhou XJ, Guan HG, Qin L, Li P, Wang ZW, Qian HX.
    J Gastroenterol Hepatol; 2008 Sep 07; 23(9):1448-58. PubMed ID: 17683489
    [Abstract] [Full Text] [Related]

  • 12. FUP1, a gene associated with hepatocellular carcinoma, stimulates NIH3T3 cell proliferation and tumor formation in nude mice.
    Pan W, Zhang Q, Xi QS, Gan RB, Li TP.
    Biochem Biophys Res Commun; 2001 Sep 07; 286(5):1033-8. PubMed ID: 11527404
    [Abstract] [Full Text] [Related]

  • 13. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Jiang H, Dong Q, Luo X, Shi B, Wang H, Gao H, Kong J, Zhang J, Li Z.
    Cancer Lett; 2014 Jan 01; 342(1):113-20. PubMed ID: 24007863
    [Abstract] [Full Text] [Related]

  • 14. Hepatitis B virus X protein promotes hepatocellular carcinoma transformation through interleukin-6 activation of microRNA-21 expression.
    Li CH, Xu F, Chow S, Feng L, Yin D, Ng TB, Chen Y.
    Eur J Cancer; 2014 Oct 01; 50(15):2560-9. PubMed ID: 25087183
    [Abstract] [Full Text] [Related]

  • 15. CDCA7L promotes hepatocellular carcinoma progression by regulating the cell cycle.
    Tian Y, Huang C, Zhang H, Ni Q, Han S, Wang D, Han Z, Li X.
    Int J Oncol; 2013 Dec 01; 43(6):2082-90. PubMed ID: 24141559
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis.
    Qi R, An H, Yu Y, Zhang M, Liu S, Xu H, Guo Z, Cheng T, Cao X.
    Cancer Res; 2003 Dec 01; 63(23):8323-9. PubMed ID: 14678992
    [Abstract] [Full Text] [Related]

  • 20. Gene expression profiling of hepatitis B- and hepatitis C-related hepatocellular carcinoma using graphical Gaussian modeling.
    Ueda T, Honda M, Horimoto K, Aburatani S, Saito S, Yamashita T, Sakai Y, Nakamura M, Takatori H, Sunagozaka H, Kaneko S.
    Genomics; 2013 Apr 01; 101(4):238-48. PubMed ID: 23485556
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.